You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. IMMUNITYBIO INC

ImmunityBio Inc XNAS: IBRX

ImmunityBio Inc Live Share Price Today, Share Analysis and Chart

Download real time

2.47 -0.01 (-0.40%)

76.54% Fall from 52W High

4.7M XNAS Volume

XNAS 17 Apr, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share

ImmunityBio Inc Key Metrics

Default

Market Capitalization

High in industry
2,179.7

PE TTM

Negative PE TTM
-5.3

PEG TTM

Negative PEG TTM
-0.2

Price to Book

Negative Price to Book
-4.3

Institutional holding current Qtr %

Below industry Median
10

Revenue Growth Qtr YoY %

Market Leader
5,333.1

Operating Revenue growth TTM %

High in industry
2,270.6

Net Profit Qtr Growth YoY %

High in industry
74.7

Net Profit TTM Growth %

Below industry Median
29.1

Operating Profit Margin Qtr %

Negative Operating Profit Margin Qtr %
-919

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-2,334.2

Piotroski Score

Below industry Median
1

Rel Perf vs Sector quarter%

-15

RoA Annual %

Negative RoA Annual %
-93.2
All financials are in USD Million and price data in USD
VIEW MORE

7

S

17

W

2

O

2

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


ImmunityBio Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '25Dec '260250500Actual RevenueAvg. Estimate
Miss

ImmunityBio Inc's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

Current EPS
-0.6
Avg. Estimate
-0.5
Low Estimate
-0.6
High Estimate
-0.5
Current EPS
Avg. Estimate
Hit

EPS is expected to grow by 10.2% in FY25

Consensus Recommendation

4 ANALYST Recommendations
STRONG BUY

Created with Highcharts 7.2.21Buy3Strong Buy

The consensus recommendation from 4 analysts for ImmunityBio Inc is STRONG BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

ImmunityBio Inc Stock Analysis

ImmunityBio Inc stock analysis with key metrics, changes, and trends.

ImmunityBio Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$14.74 M2270.58%positive

Annual Revenue rose 2,270.58%, in the last year to $14.74 M. Its sector's average revenue growth for the last fiscal year was 7.54%.

Annual Net Profit$413.56 M29.09%positive

Annual Net Profit rose 29.09% in the last year to $413.56 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

Price to Earning Ratio-5.27-negative

Price to Earning Ratio is -5.27, which is negative.

Stock Price$2.47-53.13%negative

Stock Price fell 53.13% and underperformed its sector by 60.46% in the past year.

Quarterly Revenue$7.55 M5333.09%positive

Quarterly Revenue rose 5,333.09% YoY to $7.55 M. Its sector's average revenue growth YoY for the quarter was 5.84%.

Quarterly Net profit$59.16 M74.65%positive

Quarterly Net profit rose 74.65% YoY to $59.16 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

Mutual Fund Holding6.85 %-0.97%negative

Mutual Fund Holding decreased by 0.97% in the last quarter to 6.85.

Interest Coverage Ratio-2.14-negative

Interest Coverage Ratio is -2.14, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding10.00 %0.01%positive

Institutional Holding increased by 0.01% in the last quarter to 10.

VIEW LESS


Loading data..

ImmunityBio Inc - Company Profile

What does ImmunityBio Inc do?

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

ImmunityBio Inc Management structure

All Gross Remunerations are in USD
Dr. Patrick Soon-Shiong, F.A.C.S.,M.D.
Executive Chairman of the Board and Global Chief Scientific and Medical Officer
-
2024
Gross Remuneration
Year
Ms. Regan J. Lauer
Chief Accounting Officer
-
2024
Gross Remuneration
Year
Dr. Barry J. Simon, M.D.
Chief Corporate Affairs Officer and Director
-
2024
Gross Remuneration
Year
Mr. Richard Adcock
Chief Executive Officer, President and Director
-
2024
Gross Remuneration
Year
Mr. David C. Sachs
Chief Financial Officer
-
2024
Gross Remuneration
Year

ImmunityBio Inc Board of directors

All Gross Remunerations are in USD
Mr. John Owen Brennan
Independent Director
-
2025
Gross Remuneration
Year

ImmunityBio Inc FAQ

How is ImmunityBio Inc today?
ImmunityBio Inc today is trading in the red, and is down by -0.40% at 2.47.
ImmunityBio Inc is currently trading down -0.40% on an intraday basis. In the past week the stock fell -6.08%. stock has been down -15.99% in the past quarter and fell -53.13% in the past year. You can view this in the overview section.